Report LibraryAll Reports
Datamonitor Healthcare CV&Met Disease Analysis: Type 2 Diabetes
December 17, 2020The type 2 diabetes market is dynamic and complex. In the non-insulin segment, while older generic drugs are widely used, especially first-line metformin in the US and EU, the more novel branded drugs are used in a sizable minority of patients, generating over $26bn in sales in 2019. The DPP-IV inhibitors have been the most commonly used of these, due to their safety and tolerability, albeit with intermediate efficacy, but in the important US market, GLP-1 agonists have overtaken them in usage and SGLT-2 inhibitors are catching up. The increased usage of GLP-1 agonists and SGLT-2 inhibitors has been spurred by recommendations in a 2018 ADA/EASD consensus report for patients with relevant co- morbidities due to their benefits on MACE, and for the SGLT-2 inhibitors in particular, heart failure and renal impairment. This is expected to continue to grow these classes, though clinical inertia still needs to be overcome among a number of physicians, and intense pricing competition, with increasing rebates in the US, is typical across the indication. However, loss of exclusivity will start to take a toll on all of these classes over the next 10 years, particularly starting with patent expirations for the leading DPP-IV inhibitor, Januvia, in 2022.
This Datamonitor Healthcare report contains a Disease Analysis module.
|Indications Covered:||Diabetes Mellitus, Type II|